Adrian Cotterell
Virginia Commonwealth University
Internal medicineUrologySurgeryPathologyGene expressionRenal functionRetrospective cohort studyProspective cohort studyImmunologyTumor microenvironmentLiver cancerHepatitis C virusHepatitis CTransmission (medicine)Liver diseaseCirrhosisHepatitis BHepatocellular carcinomaPancreas transplantationLiver transplantationUrineSingle CenterKidneyKidney transplantationCreatinineFibrosisHepatitis B virusTacrolimusTransplantationLiving donor liver transplantationPalliative careIncidence (epidemiology)Cancer researchMolecular medicineMedicineGastroenterology
Publications 27
#1Gaurav Gupta (VCU: Virginia Commonwealth University)H-Index: 16
#2Idris Yakubu (VCU: Virginia Commonwealth University)H-Index: 4
Last. M Shinbashi (VCU: Virginia Commonwealth University)
view all 0 authors...
Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant recipients (D+/R- transplants), may be limited in 'real-world' application by costs and delayed access to DAAs. We previously reported HCV transmission of 13% among D+/R- transplants with 2-4 day pangenotypic sofosbuvir/velpatasvir (SOF/VEL) peri-operative prophylaxis, where one patient with HCV transmission was a non-resp...
#1Angela Sickels (VCU: Virginia Commonwealth University)
#2Keyur B. Shah (VCU: Virginia Commonwealth University)H-Index: 23
Last. Amit Sharma (VCU: Virginia Commonwealth University)H-Index: 18
view all 13 authors...
BACKGROUND Combined heart-liver transplantation (CHLT) is the only curative option for patients with concomitant pathology affecting the heart and liver. In some cases, the native livers of familial amyloidosis (FA) patients may be suitable for domino transplantation into other recipients. METHODS Retrospective analysis (2013 to 2019) of all CHLT at our center was performed. Continuous data were presented as mean with standard deviation and discrete variables as percentages. RESULTS Familial amy...
#2Seung Duk LeeH-Index: 5
Last. Marlon F. LevyH-Index: 53
view all 11 authors...
#2Seung Duk LeeH-Index: 5
Last. Adrian CotterellH-Index: 13
view all 11 authors...
#1Ashley Rosenberg (VCU: Virginia Commonwealth University)H-Index: 3
#2Katarzyna Trebska-McGowan (VCU: Virginia Commonwealth University)H-Index: 3
Last. Chandra Bhati (VCU: Virginia Commonwealth University)H-Index: 16
view all 11 authors...
Hepatic artery aneurysms are rare, but their diagnosis is important because of high mortality and complications. Common risk factors for developing these aneurysms include hypertension, vascular disease, pancreatitis, diabetes, tobacco use, autoimmune diseases, and previous transplantation. Frequent imaging for trauma and tumor surveillance has increased the incidence of naive hepatic aneurysms. These aneurysms can be difficult to manage, and it can be challenging to decide the correct treatment...
#1Gaurav Gupta (VCU: Virginia Commonwealth University)H-Index: 16
#2Idris Yakubu (VCU: Virginia Commonwealth University)H-Index: 4
Last. Richard K. Sterling (VCU: Virginia Commonwealth University)H-Index: 77
view all 24 authors...
We conducted an adaptive design single-center pilot trial between October 2017 and November 2018 to determine the safety and efficacy of ultra-short-term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)-nucleic acid test (NAT) positive donors to HCV negative kidney recipients (D+/R-). In Group 1, 10 patients received one dose of SOF/VEL (sofusbuvir/velpatasvir) pretransplant and one dose on posttransplant Day 1. In Group 2A (N = 15) and th...
23 CitationsSource
#1Kunal Yadav (VCU: Virginia Commonwealth University)H-Index: 6
#2Adrian Cotterell (VCU: Virginia Commonwealth University)H-Index: 13
Last. Marlon F. Levy (VCU: Virginia Commonwealth University)H-Index: 26
view all 9 authors...
Abstract This case describes a 34 year old female who underwent an HLA identical living donor kidney transplant with a positive flow cytometric crossmatch (FCXM), but without any donor specific antibody (DSA). Tests to detect non-HLA antibody and autoantibody were negative. Allograft functioned well without rejection. She later received a pancreas allograft, again with a weakly positive FCXM, without DSA. After good initial graft function, she developed hyperglycemia six weeks posttransplant. Cr...
2 CitationsSource
#1Gaurav Gupta (VCU: Virginia Commonwealth University)H-Index: 16
#2Le Kang (VCU: Virginia Commonwealth University)H-Index: 15
Last. Richard K. Sterling (VCU: Virginia Commonwealth University)H-Index: 77
view all 15 authors...
The use of kidneys from hepatitis C virus (HCV) positive (D+) deceased donors for HCV negative recipients (R-) might increase the donor pool. We analyzed the national OPTN registry from 1994-2014 to compare the outcomes of HCV D+/R- (n=421) to propensity matched HCV donor negative (D-)/R- kidney transplants, as well as with, wait listed patients who never received a transplant, in a 1:5 ratio (n = 2105, per matched group). Both 5-year graft (44% vs. 66%; p < 0.001) and patient survival (57% vs. ...
14 CitationsSource
#1Ashley J. Limkemann (VCU: Virginia Commonwealth University)H-Index: 3
#2Luke G. Wolfe (VCU: Virginia Commonwealth University)H-Index: 50
Last. Gaurav Gupta (VCU: Virginia Commonwealth University)H-Index: 16
view all 12 authors...
Concern over transmission of viral infections has been reported to result in higher discard rates of high infectious risk kidneys (HIR) although data on actual viral transmission rates are lacking. At our center, we performed 89 HIR and 533 non-HIR kidney transplants (KTs) between 2004 and 2011. Follow-up screening labs in recipients of HIR kidneys tested for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus did not reveal any cases of viral transmission over median follow-u...
10 CitationsSource
#1Gaurav Gupta (VCU: Virginia Commonwealth University)H-Index: 16
#2A. Regmi (VCU: Virginia Commonwealth University)H-Index: 1
Last. Anne L. King (VCU: Virginia Commonwealth University)H-Index: 17
view all 11 authors...
There is no literature on the use of belatacept for sensitized patients or regrafts in kidney transplantation. We present our initial experience in high immunologic risk kidney transplant recipients who were converted from tacrolimus to belatacept for presumed acute calcineurin inhibitor (CNI) toxicity and/or interstitial fibrosis/tubular atrophy. Six (mean age = 40 years) patients were switched from tacrolimus to belatacept at a median of 4 months posttransplant. Renal function improved signifi...
36 CitationsSource